Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

multi-epitope folate receptor alpha peptide vaccine

A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulating and antineoplastic activity. Upon administration, the multi-epitope FR alpha peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	FR alpha peptide vaccine FRα peptide vaccine
Abbreviation:	HuFR-1

multi-epitope folate receptor alpha peptide vaccine

Search NCI's Drug Dictionary